Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PFIZER INC Director's Dealing 2020

Jul 9, 2020

29831_dirs_2020-07-09_942951c7-dc1c-4247-9e90-5f8552a1df56.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2020-06-29

Reporting Person: SAHNI PAYAL (Executive Vice President)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 13393.0000 Direct
Common Stock 8662.0000 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Phantom Stock Units SSP $ Common Stock (7524.0000) Direct
Stock Appreciation Rights $30.5900 2021-02-25 Common Stock (9483.0000) Direct
Stock Appreciation Rights $30.5900 2023-02-25 Common Stock (8475.0000) Direct
Stock Appreciation Rights $34.0600 2022-02-23 Common Stock (13190.0000) Direct
Stock Appreciation Rights $34.0600 2024-02-23 Common Stock (10950.0000) Direct
Stock Appreciation Rights $34.1000 2025-02-27 Common Stock (18102.0000) Direct
Stock Appreciation Rights $34.1000 2027-02-27 Common Stock (15509.0000) Direct
Stock Appreciation Rights $35.7400 2023-02-22 Common Stock (14449.0000) Direct
Stock Appreciation Rights $35.7400 2025-02-22 Common Stock (12079.0000) Direct
Stock Appreciation Rights $43.3500 2024-02-28 Common Stock (12786.0000) Direct
Stock Appreciation Rights $43.3500 2026-02-28 Common Stock (10775.0000) Direct

Footnotes

F1: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2: Each unit represents one phantom share of common stock.

F3: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F4: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.